COMMENTARY

COMMENTARY/Wholesalers Need to Analyze Causes of Their Failure

August 24, 2009
The top-four drug wholesalers have reported their business results for the first quarter of FY2009 (April-June). All four of the companies except Mediceo Paltac posted growth rates in sales higher than the industry average of about 2.1% compared to the…

To read the full story

COMMENTARY

A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Philip Carrigan

In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…

By Tatsuya Otsuka

Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…